Than Aw
Geriatric Medicine · Fresno, CANPI 1740295419
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 283 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Among geriatric medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 283 payments — averaging $45.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$2K
- Lilly USA, LLC$1K
- AstraZeneca$960
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$872
- Bayer$822
- plus $5K from 25 others
Across 31 payments — averaging $2246.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$70K
What the payments were for
- Food & beverage$12,66499%
- Education$851%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 64 | $1,738 |
| Regeneron Healthcare Solutions, Inc. | 41 | $1,591 |
| Lilly USA, LLC | 41 | $1,414 |
| AstraZeneca | 11 | $960 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $872 |
| Bayer | 18 | $822 |
| Novo Nordisk | 24 | $693 |
| Johnson & Johnson | 7 | $632 |
| Boehringer Ingelheim | 11 | $474 |
| Incyte Corporation | 3 | $373 |
| Dexcom, Inc. | 2 | $249 |
| Biohaven Pharmaceuticals, Inc. | 2 | $246 |
| Otsuka America Pharmaceutical, Inc. | 2 | $227 |
| Avanir Pharmaceuticals, Inc. | 6 | $218 |
| Pfizer | 2 | $215 |
| Amgen | 5 | $208 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $174 |
| Novartis | 6 | $172 |
| Ironwood Pharmaceuticals, Inc | 1 | $143 |
| Merck | 3 | $134 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Alkermes, Inc. | 1 | $125 |
| Neurocrine Biosciences, Inc. | 1 | $125 |
| Astellas Pharma US Inc | 1 | $125 |
| AbbVie | 1 | $125 |
| Madrigal Pharmaceuticals | 1 | $124 |
| Galderma Laboratories, L.p. | 1 | $121 |
| Ipsen Biopharmaceuticals, Inc | 1 | $114 |
| Biodelivery Sciences International, Inc. | 1 | $97 |
| Sanofi-aventis U.S. LLC | 2 | $68 |
| Sanofi | 2 | $46 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,749 in reported general payments places this provider in the 95th percentile of 494 geriatric medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 100 | $80,456 |
| MounjaroTirzepatide | 67 | $68,195 |
| OzempicSemaglutide | 64 | $62,951 |
| TrulicityDulaglutide | 59 | $57,213 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 87 | $54,481 |
| RybelsusSemaglutide | 50 | $47,001 |
| EliquisApixaban | 26 | $27,943 |
| EntrestoSacubitril/Valsartan | 16 | $11,878 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 211 | $10,498 |
| JanuviaSitagliptin Phosphate | 15 | $10,458 |
| KerendiaFinerenone | 12 | $10,237 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $9,085 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $8,374 |
| MyrbetriqMirabegron | 16 | $7,711 |
| LinzessLinaclotide | 11 | $6,857 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,414 | $125,408126 claims |
| Novo NordiskOzempic, Rybelsus | $693 | $109,952114 claims |
| Boehringer IngelheimJardiance | $474 | $80,456100 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,738 | $63,566111 claims |
| PfizerEliquis | $215 | $27,94326 claims |
| NovartisEntresto | $172 | $11,87816 claims |
| MerckJanuvia | $134 | $10,45815 claims |
| BayerKerendia | $822 | $10,23712 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $218 | $8,37412 claims |
| Astellas Pharma US IncMyrbetriq | $125 | $7,71116 claims |
| AbbVieLinzess | $125 | $6,85711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 494 geriatric medicine providers in California.
Other geriatric medicine in Fresno
- Dzung TrinhFresno$4K
- Robert FeldmanLaguna Hills$1.2M
- Oscar ChienSan Gabriel$208K
- Anders NybergSan Diego$160K
- Paul AisenSan Diego$70K
- Wayne ChenLos Angeles$40K
- Vincent HoLancaster$32K
- Kathryn SewellSan Francisco$26K
- Stephen HenryPasadena$25K
- Chaewon SongGarden Grove$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.